From Nasdaq: 2025-03-27 19:05:00

Co-Diagnostics, Inc. (CODX) reported a quarterly loss of $0.36 per share, missing the Zacks Consensus Estimate. The company’s revenues for the quarter ended December 2024 were $0.15 million, significantly below expectations. Despite this, CoDiagnostics has outperformed consensus EPS estimates in two of the last four quarters. The stock has declined 44.5% year-to-date.

Investors are curious about the future of CoDiagnostics stock. Analysts suggest monitoring the company’s earnings outlook and estimate revisions. The Zacks Rank for CODX is currently #3 (Hold), indicating expected performance in line with the market. The current consensus EPS estimate for the company is -$0.34 for the upcoming quarter.

Medpace (MEDP), another company in the Medical Services industry, is set to report its quarterly earnings on April 21. Analysts expect Medpace to post earnings of $3.05 per share, a decrease from the previous year. The company’s revenues are forecasted to be $530.62 million, up 3.8% from the same quarter last year.

For potential investors, Zacks Investment Research provides insights on the best stocks to buy, including Co-Diagnostics, Inc. and Medpace Holdings, Inc. The Zacks Rank stock-rating system has a history of outperforming the S&P 500, offering valuable guidance for investment decisions. Stay informed with the latest recommendations from Zacks Investment Research.



Read more at Nasdaq: Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates